tion) over a treatment period of 5 weeks in patients with osteoarthritis of the hip. Initially, the manipulative therapy was more effective in reducing pain and increasing function, but it lost efficacy over time. Additional clinical studies are warranted to obtain information about the efficacy of manipulation therapy and to determine whether there are particular subgroups of patients who are most likely to benefit from this intervention. 1 I agree with Beaty et al. that there are now a number of effective surgical options, before a total hip arthroplasty, that may be effective in patients with osteoarthritis of the hip. Arthroscopic or open operative techniques used for anterior femoral impingement resulting from acetabular dysplasia are reported to reduce pain and improve function and to prolong the time until total hip arthroscopy is required. 2, 3 In addition, osteotomies of the femur, pelvis, or both can be performed to prolong the time to total joint arthroplasty. Although there are data on the efficacy of these techniques from case reports and reports on small case series, additional long-term follow-up is still required to determine which patient population with osteoarthritis of the hip is likely to benefit from these joint-saving techniques. 
1.

2.
3.
More on HIV-Associated Kaposi's Sarcoma
To the Editor: The AIDS Malignancy Consortium, a multicenter cooperative group funded by the National Cancer Institute, has enrolled 442 patients who have human immunodeficiency virus (HIV) infection and measurable Kaposi's sarcoma in a series of therapeutic trials since 1996 (Table 1) .
Our data suggest that persistent Kaposi's sarcoma despite apparently effective antiretroviral therapy is not a rare, isolated, or recent phenomenon, as suggested by Maurer and colleagues in their letter to the editor (Sept. 27 issue). 1 On the contrary, our findings indicate that since the introduction of effective antiretroviral therapy, many patients with AIDS-associated Kaposi's sarcoma have CD4 counts above the level typically associated with susceptibility to opportunistic diseases. Furthermore, although effective HIV suppression has been correlated with regression of Kaposi's sarcoma after antiretroviral therapy, 2 a substantial proportion of our patients had undetectable HIV viral loads.
These findings raise important questions about the mechanisms that control the progression of human herpesvirus 8 and Kaposi's sarcoma. They also suggest a need for studies to identify clinically relevant correlates that can distinguish between patients whose Kaposi's sarcoma responds to antiretroviral therapy and those who do not have such a response. These factors may include age, duration of HIV infection, human herpesvirus 8 viral load, and patterns of viral gene expression within tumors. viral loads, the duration of HIV infection, the CD4 nadirs of the subjects, the temporal relationship with the presentation of Kaposi's sarcoma lesions, and the response to antiretroviral treatment. Our patients have persistent Kaposi's sarcoma despite sustained high CD4 counts and undetectable viral loads for more than 2 years. The median CD4 nadir in our group is 340 per cubic millimeter, with a median duration of HIV infection of 18 years. We encourage Krown et al. and others to publish their data more fully.
